Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 6 Fallopian Tube Neoplasms 4 Carcinoma, Ovarian Epithelial 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Platinum-resistant Ovarian Cancer 1 Ovarian Cancer Recurrent 1 Melanoma 1 Lymphoma, Follicular 1 Lymphoma 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Adenoviridae Infections 1

Interventions

pembrolizumab 2 poly(I).poly(c12,U) 1 liposomal doxorubicin 1 Platinum Compounds 1 Paclitaxel 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × 1-dodecylpyridoxal × 1 year × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡